You are here

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): ...

Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, et al.

J Clin Oncol 35, 2017 (suppl; abstr 4004)

Editorial comment from Prof Lordick & Dr Smyth:
The perioperative combination chemotherapy FLOT (5-FU, Leucovorin, Oxaliplatin und Docetaxel) achieved a better progression-free and overall survival compared with ECF/ECX (Epirubicin, Cisplatin, 5-FU/Capecitabine) in patients with locally advanced operable gastric cancer or adenocarcinoma of the oesophago-gastric junction. The safety of both regimens was comparable. Perioperative complications and mortality were not increased with FLOT. In conclusion, ECF/ECX should not be used anymore. Whether patients with concomittant diseases or old patients should be treated with less intensive chemotherapy, e.g. with FLO, remains an individual decision at the current timepoint. FLOT can now be regarded as a new standard regimen in patients with locally advanced gastric cancer and adenocarcinoma of the oesophago-gastric junction.



The MAGIC trial established perioperative (periop) epirubicin, cisplatin, and 5-FU (ECF) as a standard treatment for patients (pts) with operable esophagogastric cancer, but survival continues to remain poor. FLOT4 (NCT01216644) is amulticenter, randomized, investigator-initiated, phase 3 trial. It compares the docetaxel-based triplet FLOT with the anthracycline-based triplet ECF/ECX as a periop treatment for pts with resectable gastric or GEJ adenocarcinoma.


Eligible pts of stage $cT2 and/or cN+ were randomized to either 3 preoperative and 3 post-operative 3-week cycles of ECF/ECX (epirubicin 50 mg/ m2, cisplatin 60 mg/m², both d1, and 5-FU 200 mg/m² as continuous infusion or capecitabine 1250 mg/m2 orally d1-21) or 4 pre-operative and 4 post-operative 2-week cycles of FLOT (docetaxel 50 mg/m2, oxaliplatin 85 mg/m², leucovorin 200 mg/m², and 5-FU 2600 mg/m² as 24-hour infusion, all d1). The primary endpoint was overall survival (OS; 80% power; HR of 0.76; 2-sided log-rank test at 5% type I error).


Between Aug 2010 and Feb 2015, 716 pts (360 ECF/ECX; 356 FLOT) were randomly allocated. Baseline characteristics were similar between arms (overall, male 74%; median age 62; cT3/T4 81%; cN+ 80%; GEJ 56%). 91%and 37% of pts with ECF/ECX and 90% and 50%with FLOT completed planned pre-operative and post-operative cycles, respectively.Median follow-up was 43mon. 369 pts died (203 ECF/ECX; 166 FLOT). FLOT improved OS (mOS, 35mon with ECX/ECF vs. 50 mon with FLOT; HR 0.77 [0.63 - 0.94]; p = 0.012). 3y OS rate was 48% with ECF/ECX and 57% with FLOT. FLOT also improved PFS (mPFS, 18 mon with ECX/ECF vs. 30 mon with FLOT; HR 0.75 [0.62 - 0.91]; p = 0.004). Periop complications were 50% with ECF/ECX and 51% with FLOT. 30- and 90-day mortality was 3% and 8% with ECF/ECX and 2% and 5% with FLOT. There was more G3/4 nausea and vomitingwith ECF/ECX andmoreG3/4 neutropenia with FLOT.


Periop FLOT improved outcome in patients with resectable gastric and GEJ cancer compared to periop ECF/ECX. Clinical trial information: NCT01216644.

All content © 2017 American Society of Clinical Oncology. All rights reserved.

Search this site

Search form

ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies

Welcome and introduction - Florian Lordick


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content

This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.